Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Optina Retina Scans to Detect the Likeley Cerebral Amyloid Status (CAS) as Determined by Prospective PET Imaging

NCT05215782 is registered in ClinicalTrials.gov with Optina Diagnostics Inc. as lead sponsor.

NCT NCT05215782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05215782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Optina Retina Scans to Detect the Likeley Cerebral Amyloid Status (CAS) as Determined by Prospective PET Imaging
Lead sponsor
Optina Diagnostics Inc.
Phase
Observational
Overall status
Completed
Start date
March 14, 2022
Completion date
March 16, 2023
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease